A novel strategy for designing specific gelatinase A inhibitors: Potential use to control tumor progression

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 3, 2004, Pages 277-282

  Augé, Franck ^a   Hornebeck, William ^b   Laronze, Jean Yves ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Galardin; Gelatinase A; Ilomastat; Matrix metalloproteases (MMP); MMP 2; Zinc binding group (ZBG)

Indexed keywords

CGS 27023A; DOXYCYCLINE HYCLATE; GELATINASE A; GELATINASE A INHIBITOR; GELATINASE INHIBITOR; HALOFUGINONE; HYDROXAMIC ACID; ILOMASTAT; LIGAND; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PRINOMASTAT; PYRIDINE DERIVATIVE; REBIMASTAT; TOLUENESULFONIC ACID DERIVATIVE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; ZINC;

ARTHRALGIA; BREAST CANCER; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LUNG CANCER; NONHUMAN; OSTEOPOROSIS; PANCREAS CANCER; REVIEW; TUMOR GROWTH;

EID: 1342321868     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.10.006     Document Type: Review

References (20)

1. Hornebeck W., Maquart F.X. Proteolyzed matrix as a template for the regulation of tumor progression. Biomed. Pharmacother. 57:2003;223-230.
2. Hornebeck W., Emonard H., Monboisse J.C., Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin. Cancer Biol. 12(3):2002;231-241.
3. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2(3):2002;161-174.
4. Vihinen P., Kahari V.M. Matrix metalloproteinase in cancer prognostic markers and therapeutic targets. Int. J. Cancer. 99:2002;157-166.
5. Itoh T., Tanioka M., Yoshida H., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58(5):1998;1048-1051.
6. Whittaker M., Floyd D.C., Brown P., Gearing A. Chem. Rev. 99:1999;2735.
7. Babine R.E., Bender S.L. Chem. Rev. 97:1997;1359.
8. Skiles J.W., Gonnella N.C., Jeng A.Y. Curr. Med. Chem. 8:2001;425.
9. Leung D., Abbenante G., Fairlie D.P. J. Med. Chem. 43:2000;305.
10. Booth B., Glassman R., Ma P. Oncology's trials. Nature Rev. Drug Discovery. 2:2003;609.
11. Doherty T.M., Asotra K., Pei D.et al. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Therap. Patents. 12(5):2002;665-707.
12. Augé F. Unpublished results.
13. Marcq V., Mirand C., Decarme M., Emonard H., Hornebeck W. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3. Bioorg. Med. Chem. Lett. 13:2003;2843-2846.
14. Augé F., Hornebeck W., Decarme M., Laronze J.Y. Improved gelatinase A selectivity by novel zinc binding groups containing galardin derivatives. Bioorg. Med. Chem. Lett. 13:2003;1783-1786.
15. Puerta D.T., Cohen S.M. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg. Chem. 42:2003;3423-3430.
16. Lovejoy B., Hassel A.M., Luther M.A., Weigl D., Jordan S.R. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry. 33(27):1994;8207-8217.
17. Scozzafava A., Supuran C.T. Protease inhibitors - Part 5. Alkyl/arylsulfonyl- and arylsulfonylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase. Eur. J. Med. Chem. 35(3):2000;299-307.
18. Hajduk P.J., Shuker S.B., Nettesheim D.G.et al. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 45:2002;5628-5639.
19. Bremer C., Tung C.H., Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med. 7:2001;743-748.
20. Cristofanilli M., Charnsangavej C., Hortobagyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev. Drug Discovery. 1:2002;415-426.